Forbion’s Post

Interested in the intersection of research and therapeutic development? Our latest case study explores the Functional Assessment of Properdin and methods to assess AP-modulation, providing valuable insights into the evolving landscape of complement therapeutics. https://hubs.ly/Q02CcWvG0 #ComplementingLifeScience #AnswersinLifeScience #Complementsystem #Complementbiology #AlternativePathway #Properdin #drugdevelopment

Cerevel Therapeutics announces positive topline results for Tavapadon in phase 3 adjunctive trial for people living with Parkinson’s disease. The TEMPO-3 trial evaluated its efficacy, safety and tolerability met the primary endpoint and key secondary endpoint. The neurotransmitter dopamine is linked to working memory and motor movement, and the loss of dopamine-producing neurons in the brain result in Parkinson’s disease. Tavapadon is a selective dopamine D1/D5 receptor partial agonist for the improved motor control. While most dopamine agonists target and stimulate D2/D3 dopamine receptors, Tavapadon is the only D1/D5 selective partial agonist in clinical development for PD. Chemenu supports your scientific research and drug discovery. Check our product catalog: https://lnkd.in/gdhhbE9D #PD #Phase3 #motor #Dopamine #Receptors #D1 #D1R #D5 #partial #agonist

#OrigiGator Rise Therapeutics, a University of Florida #startup and clinical-stage biotechnology company, has marked a crucial milestone by enrolling its first patient in the Phase 1 clinical trial for R-2487, a promising treatment for rheumatoid arthritis. Gary Fanger, the President and CEO of Rise Therapeutics, emphasizes the importance of this achievement in advancing innovative medicines for individuals grappling with this chronic disorder, impacting up to 0.24% of the world population and 1% of the US population. 🩺 This first-in-human clinical trial (NCT05961592) aims to delve into the safety, pharmacodynamics, and clinical activity of R-2487, offering hope for enhanced understanding and treatment options for those affected by rheumatoid arthritis. 🚀👩⚕️ Find the full story, here!▶️ https://lnkd.in/eVXXcRvP

Exciting insights on China's NRDL 2023! Our article covers the latest developments, from oncology breakthroughs to rare disease triumphs. A must-read for anyone in healthcare. Check it out here: https://ow.ly/2wbS30syXGA #Healthcare #Pharma #Biotech #MarketStrategy #SimonKucher

Tryptamine Therapeutics' Chief Scientific Officer, Dr. Jim Gilligan, discusses the company's Phase 2a IBS study at MGH. Jim not only conceptualized utilizing an IV-infusion of Psilocin to overcome the many deficiencies in Oral Psilocybin in Neuropsychiatry, he is also the named patent-holder for this invention. Thanks Jim! (James Gilligan) #Psilocin #Psilocybin #Neuroplasticity #Psychedelic #IVinfusion #Tryptherapeutics

Exciting insights on China's NRDL 2023! Our article covers the latest developments, from oncology breakthroughs to rare disease triumphs. A must-read for anyone in healthcare. Check it out here: https://ow.ly/NUhi30szl8B #Healthcare #Pharma #Biotech #MarketStrategy #SimonKucher

Came across this great read about the use of metabolomics in drug discovery. It is definitely a powerful tool that complements our traditional ways to examine and evaluate the favorability of drug candidates for therapeutic development and identify their mechanisms of action. At MAX BioPharma, in collaboration with scientists at Metaba, we have started to apply metabolomics in our drug discovery efforts and development of our oxysterol drug candidates for multiple indications including non-alcoholic steatohepatitis (NASH), idiopathic pulmonary fibrosis (IPF), cystic fibrosis (CF), atherosclerosis, and chronic inflammation. Large amounts of insightful information are derived from metabolomic studies, and hopefully soon we will begin to share our findings with the scientific community. #Oxysterol #Metabolomics #NASH #IPF #Atherosclerosis #Cysticfibrosis #Inflammation #MAXBioPharma #Metaba Philip Sell Metaba Jaejin (Joey) Lee Eric Michel, PhD https://lnkd.in/g_xdSU5Q

Groundbreaking research news: CurePSP has joined the Accelerating Medicines Partnership® in Parkinson’s Diseases and Related Disorders (AMP® PDRD). This initiative, led by the Foundation for the National Institutes of Health (FNIH), aims to better differentiate Parkinson’s disease from related neurodegenerative disorders, including progressive supranuclear palsy (PSP), multiple system atrophy (MSA) and corticobasal degeneration (CBD), to enable earlier diagnoses, more timely interventions and better outcomes. CurePSP is committed to ensuring that this focus on early and accurate diagnosis for PSP, MSA, and CBD drives meaningful progress in improving patient care. We join this effort alongside several other key partners, including Aligning Science Across Parkinson’s | ASAP, C2N Diagnostics, Denali Therapeutics, GSK, The Michael J. Fox Foundation for Parkinson's Research and Sanofi, all working together to push the boundaries of research to make a tangible impact.  #PSP #MSA #CBD #Parkinsons #Neurodegeneration #FNIH #CurePSP #EarlyDiagnosis #NIH

Latest Updates in Pharma 🌐🧬 1. Tonix Pharmaceuticals sees potential market expansion for Tonmya due to NASEM's new Long COVID definition, increasing its reach and impact. 💊🌟 2. Halia Therapeutics, Inc. and Biolexis Therapeutics, Inc. identify a small molecule for treating neuroinflammatory diseases like Parkinson's, utilizing AI-powered MolecuLern. 🧠✨ 3. Fujirebio Diagnostics, Inc. and CENTOGENE partner to advance Alzheimer's diagnostics, aiming to improve early detection and treatment. 🧬🤝 Stay informed with Pharma Now! Read more news at- https://lnkd.in/dh36nZ8Y Share your thoughts on these updates in the comments below! 💬 #PharmaNow #PharmaNews #HealthcareInnovation #GlobalPharma #Neuroinflammation #Alzheimers #LongCOVID #Fibromyalgia #DrugDevelopment

InMed Pharmaceuticals Announces Favorable Behavioral Outcomes with INM-901 in Long-Term Preclinical #Alzheimers Disease Study, Confirming Previous Short-Term Pilot Study Data "We are highly encouraged by the initial data sets from this long-term dosing study, which support the previously observed improvements in behavioral outcomes seen in our initial short-term #preclinical #Alzheimer’s proof-of-concept study. INM-901 continues to demonstrate potential by targeting multiple biological pathways linked to Alzheimer’s disease and may have potential to address the critical need for effective treatments." ~ Dr. Eric Hsu, InMed’s Senior Vice President of Preclinical Research and Development Full news release: https://ow.ly/HzKL50SNpqV $INM